Oxygenta Pharmaceutical Ltd vs CIPLA LTD
A side-by-side comparison of Oxygenta Pharmaceutical Ltd (524636) and CIPLA LTD (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads 524636 vs CIPLA on 8 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability13
- Growth10
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
CIPLA takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
524636 takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company's median sales growth is 22.1% of last 10 years"]
- − ["Company has low interest coverage ratio."]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.